Review of phase I and II trials for Wilms' tumour – Can we optimise the search for novel agents?

Jesper Brok, Kathy Pritchard-Jones, James I. Geller, Filippo Spreafico

Research output: Contribution to journalReview article

7 Citations (Scopus)

Abstract

Survival rates for patients with Wilms' tumour (WT) approximate 90% with refined use of currently available interventions. However, a subgroup of patients, with initial high-risk histopathology or relapsing disease, have a poor prognosis, and it is a challenge to identify and prioritise the development of new innovative approaches for these subgroups. We conducted a systematic literature search for published phase I and II clinical trials that registered patients with WTs and characterised the early phase trial activity, quantified response rates and highlighted avenues for further development. We identified 63 trials (48 phase I, three phase I/II, and 12 phase II trials) enrolling 214 patients with WTs, alongside other malignancies. The number of annually recruited WTs did not change significantly and was less than 20% of the potential candidates. The vast majority of the trials were conducted in North America, and 56 different interventions were investigated, including conventional chemotherapy and biologically targeted therapies. Overall, 33 WTs revealed some degree of tumour control. Of these, five patients demonstrated complete remission (2%), 15 patients partial response (7%) and 13 patients stable disease (6%). None of the included novel biologically targeted therapies emerged as promising interventions, and only conventional chemotherapy was able to induce a complete and partial response. We conclude that early phase trial recruitment of WTs is below expected levels, and the clinical outcome of the included patients is dismal. Improvement of the availability and recruitment to early phase trials for WTs, especially in Europe, is needed.

Original languageEnglish
Pages (from-to)205-213
Number of pages9
JournalEuropean Journal of Cancer
Volume79
DOIs
Publication statusPublished - Jul 1 2017

Fingerprint

Wilms Tumor
Drug Therapy
Phase II Clinical Trials
Clinical Trials, Phase I
North America
Neoplasms
Survival Rate
Therapeutics

Keywords

  • Chemotherapy
  • Phase I/II trials
  • Refractory
  • Relapse
  • Targeted therapy
  • Wilms' tumour

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Review of phase I and II trials for Wilms' tumour – Can we optimise the search for novel agents? / Brok, Jesper; Pritchard-Jones, Kathy; Geller, James I.; Spreafico, Filippo.

In: European Journal of Cancer, Vol. 79, 01.07.2017, p. 205-213.

Research output: Contribution to journalReview article

@article{8cbf98cc4a804f229be2c270fb907c7d,
title = "Review of phase I and II trials for Wilms' tumour – Can we optimise the search for novel agents?",
abstract = "Survival rates for patients with Wilms' tumour (WT) approximate 90{\%} with refined use of currently available interventions. However, a subgroup of patients, with initial high-risk histopathology or relapsing disease, have a poor prognosis, and it is a challenge to identify and prioritise the development of new innovative approaches for these subgroups. We conducted a systematic literature search for published phase I and II clinical trials that registered patients with WTs and characterised the early phase trial activity, quantified response rates and highlighted avenues for further development. We identified 63 trials (48 phase I, three phase I/II, and 12 phase II trials) enrolling 214 patients with WTs, alongside other malignancies. The number of annually recruited WTs did not change significantly and was less than 20{\%} of the potential candidates. The vast majority of the trials were conducted in North America, and 56 different interventions were investigated, including conventional chemotherapy and biologically targeted therapies. Overall, 33 WTs revealed some degree of tumour control. Of these, five patients demonstrated complete remission (2{\%}), 15 patients partial response (7{\%}) and 13 patients stable disease (6{\%}). None of the included novel biologically targeted therapies emerged as promising interventions, and only conventional chemotherapy was able to induce a complete and partial response. We conclude that early phase trial recruitment of WTs is below expected levels, and the clinical outcome of the included patients is dismal. Improvement of the availability and recruitment to early phase trials for WTs, especially in Europe, is needed.",
keywords = "Chemotherapy, Phase I/II trials, Refractory, Relapse, Targeted therapy, Wilms' tumour",
author = "Jesper Brok and Kathy Pritchard-Jones and Geller, {James I.} and Filippo Spreafico",
year = "2017",
month = "7",
day = "1",
doi = "10.1016/j.ejca.2017.04.005",
language = "English",
volume = "79",
pages = "205--213",
journal = "European Journal of Cancer",
issn = "0959-8049",
publisher = "Elsevier Ltd",

}

TY - JOUR

T1 - Review of phase I and II trials for Wilms' tumour – Can we optimise the search for novel agents?

AU - Brok, Jesper

AU - Pritchard-Jones, Kathy

AU - Geller, James I.

AU - Spreafico, Filippo

PY - 2017/7/1

Y1 - 2017/7/1

N2 - Survival rates for patients with Wilms' tumour (WT) approximate 90% with refined use of currently available interventions. However, a subgroup of patients, with initial high-risk histopathology or relapsing disease, have a poor prognosis, and it is a challenge to identify and prioritise the development of new innovative approaches for these subgroups. We conducted a systematic literature search for published phase I and II clinical trials that registered patients with WTs and characterised the early phase trial activity, quantified response rates and highlighted avenues for further development. We identified 63 trials (48 phase I, three phase I/II, and 12 phase II trials) enrolling 214 patients with WTs, alongside other malignancies. The number of annually recruited WTs did not change significantly and was less than 20% of the potential candidates. The vast majority of the trials were conducted in North America, and 56 different interventions were investigated, including conventional chemotherapy and biologically targeted therapies. Overall, 33 WTs revealed some degree of tumour control. Of these, five patients demonstrated complete remission (2%), 15 patients partial response (7%) and 13 patients stable disease (6%). None of the included novel biologically targeted therapies emerged as promising interventions, and only conventional chemotherapy was able to induce a complete and partial response. We conclude that early phase trial recruitment of WTs is below expected levels, and the clinical outcome of the included patients is dismal. Improvement of the availability and recruitment to early phase trials for WTs, especially in Europe, is needed.

AB - Survival rates for patients with Wilms' tumour (WT) approximate 90% with refined use of currently available interventions. However, a subgroup of patients, with initial high-risk histopathology or relapsing disease, have a poor prognosis, and it is a challenge to identify and prioritise the development of new innovative approaches for these subgroups. We conducted a systematic literature search for published phase I and II clinical trials that registered patients with WTs and characterised the early phase trial activity, quantified response rates and highlighted avenues for further development. We identified 63 trials (48 phase I, three phase I/II, and 12 phase II trials) enrolling 214 patients with WTs, alongside other malignancies. The number of annually recruited WTs did not change significantly and was less than 20% of the potential candidates. The vast majority of the trials were conducted in North America, and 56 different interventions were investigated, including conventional chemotherapy and biologically targeted therapies. Overall, 33 WTs revealed some degree of tumour control. Of these, five patients demonstrated complete remission (2%), 15 patients partial response (7%) and 13 patients stable disease (6%). None of the included novel biologically targeted therapies emerged as promising interventions, and only conventional chemotherapy was able to induce a complete and partial response. We conclude that early phase trial recruitment of WTs is below expected levels, and the clinical outcome of the included patients is dismal. Improvement of the availability and recruitment to early phase trials for WTs, especially in Europe, is needed.

KW - Chemotherapy

KW - Phase I/II trials

KW - Refractory

KW - Relapse

KW - Targeted therapy

KW - Wilms' tumour

UR - http://www.scopus.com/inward/record.url?scp=85019259595&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85019259595&partnerID=8YFLogxK

U2 - 10.1016/j.ejca.2017.04.005

DO - 10.1016/j.ejca.2017.04.005

M3 - Review article

VL - 79

SP - 205

EP - 213

JO - European Journal of Cancer

JF - European Journal of Cancer

SN - 0959-8049

ER -